A Safety, Tolerability and Efficacy Study of Doxycycline Topical Foam Administered Topically for Prevention of Epidermal Growth Factor Receptor Inhibition Skin Toxicity, to Subjects With Cancer Receiving Cetuximab or Panitumumab
Phase of Trial: Phase II
Latest Information Update: 07 Jun 2016
At a glance
- Drugs Doxycycline (Primary)
- Indications Exanthema
- Focus Adverse reactions
- Sponsors Foamix
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 31 May 2016 Results published in a Foamix Pharmaceuticals media release.
- 31 May 2016 Data will be presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, according to a Foamix Pharmaceuticals media release.